Eyenuk EyeArt

About

Key Features

• Autonomous Retinal Disease Detection: Automatically detects diabetic retinopathy, age-related macular degeneration, and glaucoma from retinal fundus images without requiring expert human grading.
• Sub-60-Second Clinical Reporting: Analyzes retinal images and returns an easy-to-read clinical report in under 60 seconds, enabling complete imaging, grading, and reporting in a single office visit.
• Real-Time Image Quality Feedback: Provides instant feedback during image acquisition to ensure captured images meet quality standards, reducing the need for repeat visits.
• Multi-Camera Compatibility: FDA-cleared for use with multiple fundus camera models, offering flexibility for primary care clinics and diverse clinical environments.
• Global Regulatory Approvals: Holds FDA clearance, EU CE marking as a Class IIb medical device, and a Health Canada license — meeting the highest international standards for AI medical devices.

Use Cases

• Primary care clinics screening diabetic patients for retinopathy without needing a specialist referral or pupil dilation
• National health systems deploying autonomous AI eye screening at population scale to reduce preventable vision loss from diabetes
• Endocrinology and diabetology practices integrating retinal screening seamlessly into routine diabetes management appointments
• Optometry and ophthalmology offices streamlining patient workflows with automated retinal analysis and instant clinical reports
• Health insurers and payors implementing AI-driven screening programs to lower the long-term costs of late-stage diabetic eye disease

Pros

• Most Extensively Validated AI Eye Screener: Tested on over 500,000 patient visits and 2 million+ real-world retinal images, making it the most validated autonomous AI system for diabetic retinopathy screening globally.
• No Dilation or Specialist Required: Eliminates the need for pupil dilation and specialist graders, significantly improving patient comfort, clinical throughput, and access in primary care settings.
• Multi-Disease Screening in One Workflow: Screens for three major sight-threatening conditions — DR, AMD, and glaucoma — in a single, streamlined clinical encounter.
• Strong Regulatory Pedigree: FDA cleared, CE marked (Class IIb), and Health Canada licensed, providing high confidence for deployment in regulated healthcare and national health system environments.

Cons

• Clinical and Enterprise Use Only: EyeArt is designed exclusively for healthcare organizations and clinical settings; it is not accessible to individual consumers or small independent practices without a formal partnership.
• Pricing Not Publicly Listed: Costs are not disclosed on the website and require direct engagement with Eyenuk's sales team, making upfront cost comparisons difficult.
• Hardware Dependency: Requires a compatible retinal fundus camera to operate, adding hardware procurement and setup costs beyond the software investment.